



# Verona Pharma

3 March 2015

## Director's Dealing

### **VERONA PHARMA PLC - Director's Dealing**

PR Newswire

London, March 3

Verona Pharma plc

("Verona Pharma" or the "Company")

Director's Dealing

3 March 2015, Cardiff - Verona Pharma plc (AIM: VRP) today received notification that on 3 March 2015 Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 450,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at an average price of 2.432 pence per share.

Following the acquisition, Dr. Ebsworth will have an interest in the Company of 3,279,774 Ordinary Shares, representing 0.32% of the Company's issued ordinary share capital.

The Company also received notification today that on 3 March 2015 Biresh Roy, Chief Financial Officer of the Company, purchased 250,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at an average price of 2.432 pence per share.

Following the acquisition, Biresh Roy will have an interest in the Company of 750,000 Ordinary Shares, representing 0.07% of the Company's issued ordinary share capital.

-Ends-

For further information please contact:

Verona Pharma plc                      Tel: +44 (0) 20 3283 4200  
Jan-Anders Karlsson, CEO

N+1 Singer                                Tel: +44 (0)20 7496 3000  
Aubrey Powell / Jen Boorer

FTI Consulting                          Tel: +44 (0)20 3727 1000  
Julia Phillips / Simon Conway

Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company

focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, asthma and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma. Verona Pharma is also building a broader franchise around RPL554 to maximise its value, both to patients and to investors. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing.

---

For further information please contact: Verona Pharma plc

**Verona Pharma plc**

Jan-Anders Karlsson, CEO  
Tel: +44 (0)20 3283 4200  
info@veronapharma.com

**N+1 Singer (Nominated Adviser and UK Broker)**

Aubrey Powell / James White  
Tel: +44 (0)20 7496 3000

**FTI Consulting**

Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins  
Tel: +44 (0)20 3727 1000  
veronapharma@fticonsulting.com

**ICR, Inc. (US Media and Investor enquiries)**

James Heins  
Tel: +1 203-682-8251  
James.Heins@icrinc.com

Stephanie Carrington  
Tel. +1 646-277-1282  
Stephanie.Carrington@icrinc.com

---

**About Verona Pharma plc**

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 has also shown anti-inflammatory effects and been well tolerated in clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

**Forward Looking Statements**

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the development of DPI and MDI formulations of RPL554 and the potential for these formulations to increase the market opportunity for the product, if approved.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.